Corrigendum to: Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells (Evidence-based Complementary and Alternative Medicine (2013) 2013 (805639) DOI: 10.1155/2013/805639);Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Jung, Ji Hoon ^a   Kwon, Tae Rin ^a   Jeong, Soo Jin ^a,b   Kim, Eun Ok ^a   Sohn, Eun Jung ^a   Yun, Miyong ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CRYPTOTANSHINONE; CYCLIN D1; IMATINIB; JANUS KINASE; PROTEIN BCL XL; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; TANSHINONE IIA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84880155118     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2018/1295359     Document Type: Erratum

References (37)

1. Zhou L., Zuo Z., Chow M. S. S., Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology 2005 45 12 1345 1359 2-s2.0-27844511101 10.1177/0091270005282630
2. Liu A.-H., Li L., Xu M., Lin Y.-H., Guo H.-Z., Guo D.-A., Simultaneous quantification of six major phenolic acids in the roots of Salvia miltiorrhiza and four related traditional Chinese medicinal preparations by HPLC-DAD method. Journal of Pharmaceutical and Biomedical Analysis 2006 41 1 48 56 2-s2.0-33645080664 10.1016/j.jdermsci.2006.05.009
3. Ma L., Zhang X., Guo H., Gan Y., Determination of four water-soluble compounds in Salvia miltiorrhiza Bunge by high-performance liquid chromatography with a coulometric electrode array system. Journal of Chromatography B 2006 833 2 260 263 2-s2.0-33645222408 10.1016/j.jchromb.2006.01.021
4. Wang X., Morris-Natschke S. L., Lee K.-H., New developments in the chemistry and biology of the bioactive constituents of Tanshen. Medicinal Research Reviews 2007 27 1 133 148 2-s2.0-33845768814 10.1002/med.20077
5. Bi H.-C., Zuo Z., Chen X., Xu C.-S., Wen Y.-Y., Sun H.-Y., Zhao L.-Z., Pan Y., Deng Y., Liu P.-Q., Gu L.-Q., Huang Z.-Y., Zhou S.-F., Huang M., Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiotica 2008 38 2 185 222 2-s2.0-38149068306 10.1080/00498250701767675
6. Don M.-J., Shen C.-C., Syu W.-J., Ding Y.-H., Sun C.-M., Cytotoxic and aromatic constituents from Salvia miltiorrhiza. Phytochemistry 2005 67 5 497 503 2-s2.0-32244445209 10.1016/j.phytochem.2005.11.005
7. Gu M., Zhang G., Su Z., Ouyang F., Identification of major active constituents in the fingerprint of Salvia miltiorrhiza Bunge developed by high-speed counter-current chromatography. Journal of Chromatography A 2004 1041 1-2 239 243 2-s2.0-2942567865 10.1016/j.chroma.2004.04.030
8. Chen W., Liu L., Luo Y., Odaka Y., Awate S., Zhou H., Shen T., Zheng S., Lu Y., Huang S., Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prevention Research 2012 5 778 787
9. Chen W., Lu Y., Chen G., Huang S., Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anti-cancer Agents in Medicinal Chemistry. In press
10. Ge Y., Cheng R., Zhou Y., Shen J., Peng L., Xu X., Dai Q., Liu P., Wang H., Ma X., Jia J., Chen Z., Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Molecular and Cellular Biochemistry 2012 368 17 25
11. Kim J.-H., Jeong S.-J., Kwon T.-R., Yun S.-M., Jung J. H., Kim M., Lee H.-J., Lee M.-H., Ko S. G., Chen C.-Y., Kim S.-H., Cryptotanshinone enhances TNF- α -induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011 16 7 696 707 2-s2.0-80051547153 10.1007/s10495-011-0605-1
12. Lee H. J., Jung D. B., Sohn E. J., Kim H. H., Park M. N., Lew J. H., Lee S. G., Kim B., Kim S. H., Inhibition of hypoxia inducible factor alpha and astrocyte-elevated gene-1 mediates cryptotanshinone exerted antitumor activity in hypoxic PC-3 cells. Evidence-Based Complementary and Alternative Medicine 2012 2012 13 390957 10.1155/2012/390957
13. Cheng C.-Y., Su C.-C., Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Molecular Medicine Reports 2010 3 4 645 650 2-s2.0-77956671599 10.3892/mmr-00000310
14. Su C.-C., Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Experimental and Therapeutic Medicine 2012 3 3 555 559 2-s2.0-84855856952 10.3892/etm.2011.441
15. Won S.-H., Lee H.-J., Jeong S.-J., Lee H.-J., Lee E.-O., Jung D.-B., Shin J.-M., Kwon T.-R., Yun S.-M., Lee M.-H., Choi S.-H., Lü J., Kim S.-H., Tanshinone IIa induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biological and Pharmaceutical Bulletin 2010 33 11 1828 1834 2-s2.0-78249235878 10.1248/bpb.33.1828
16. Won S.-H., Lee H.-J., Jeong S.-J., Lü J., Kim S.-H., Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells. Phytotherapy Research 2012 26 5 669 674 2-s2.0-84859903322 10.1002/ptr.3616
17. Xu S., Liu P., Tanshinone II-A: new perspectives for old remedies. Expert Opinion on Therapeutic Patents 2013 23 149 153 10.1517/13543776.2013.743995
18. Yun S. M., Jeong S. J., Kim J. H., Jung J. H., Lee H. J., Sohn E. J., Lee M. H., Kim S. H., Activation of C-Jun N-terminal kinase mediates tanshinone IIA-induced apoptosis in KBM-5 chronic myeloid leukemia cells. Biological & Pharmaceutical Bulletin 2013 36 208 214
19. Buettner R., Mora L. B., Jove R., Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Research 2002 8 4 945 954 2-s2.0-0036554816
20. Vera J., Rateitschak K., Lange F., Kossow C., Wolkenhauer O., Jaster R., Systems biology of JAK-STAT signalling in human malignancies. Progress in Biophysics and Molecular Biology 2011 106 2 426 434 2-s2.0-80051672211 10.1016/j.pbiomolbio.2011.06.013
21. Tang C., Xue H.-L., Huang H.-B., Wang X.-G., Tanshinone IIA inhibits constitutive STAT3 activation, suppresses proliferation, and induces apoptosis in rat C6 glioma cells. Neuroscience Letters 2010 470 2 126 129 2-s2.0-74449089539 10.1016/j.neulet.2009.12.069
22. Shin D.-S., Kim H.-N., Shin K. D., Young J. Y., Kim S.-J., Dong C. H., Kwon B.-M., Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Research 2009 69 1 193 202 2-s2.0-58249119435 10.1158/0008-5472.CAN-08-2575
23. Choi H.-S., Cho D.-I., Choi H.-K., Im S. Y., Ryu S.-Y., Kim K.-M., Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Archives of Pharmacal Research 2004 27 12 1233 1237 2-s2.0-13744259982
24. Hur J. M., Shim J. S., Jung H. J., Kwon H. J., Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Experimental and Molecular Medicine 2005 37 2 133 137 2-s2.0-18744369947
25. Chou T.-C., Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Research 2010 70 2 440 446 2-s2.0-76549129820 10.1158/0008-5472.CAN-09-1947
26. Li W. X., Canonical and non-canonical JAK-STAT signaling. Trends in Cell Biology 2008 18 11 545 551 2-s2.0-54049101441 10.1016/j.tcb.2008.08.008
27. Sansone P., Bromberg J., Targeting the interleukin-6/Jak/stat pathway in human malignancies. Journal of Clinical Oncology 2012 30 9 1005 1014 2-s2.0-84860630975 10.1200/JCO.2010.31.8907
28. Duan H., Orth K., Chinnaiyan A. M., Poirier G. G., Froelich C. J., He W.-W., Dixit V. M., ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. Journal of Biological Chemistry 1996 271 28 16720 16724 2-s2.0-0030008812 10.1074/jbc.271.28.16720
29. Sawyers C. L., Denny C. T., Witte O. N., Leukemia and the disruption of normal hematopoiesis. Cell 1991 64 2 337 350 2-s2.0-0026017392
30. Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmermann J., Lydon N. B., Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nature Medicine 1996 2 5 561 566 2-s2.0-0029947186
31. Faderl S., Talpaz M., Estrov Z., Kantarjian H. M., Chronic myelogenous leukemia: biology and therapy. Annals of Internal Medicine 1999 131 3 207 219 2-s2.0-0033520092
32. Aggarwal B. B., Sethi G., Ahn K. S., Sandur S. K., Pandey M. K., Kunnumakkara A. B., Sung B., Ichikawa H., Targeting signal-transducer-and- activator-of-transcription-3 for prevention and therapy of cancer: Modern target but ancient solution. Annals of the New York Academy of Sciences 2006 1091 151 169 2-s2.0-33947574564 10.1196/annals.1378.063
33. Silva C. M., Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004 23 48 8017 8023 2-s2.0-7944233465 10.1038/sj.onc.1208159
34. Smirnova O. V., Ostroukhova T. Y., Bogorad R. L., JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World Journal of Gastroenterology 2007 13 48 6478 6491 2-s2.0-38349063045 10.3748/wjg.13.6478
35. Han Y., Amin H. M., Franko B., Frantz C., Shi X., Lai R., Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006 108 8 2796 2803 2-s2.0-33750632572 10.1182/blood-2006-04-017434
36. Hirano T., Ishihara K., Hibi M., Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000 19 21 2548 2556 2-s2.0-0034658541
37. Turkson J., STAT proteins as novel targets for cancer drug discovery. Expert Opinion on Therapeutic Targets 2004 8 5 409 422 2-s2.0-5444237088 10.1517/14728222.8.5.409